Hans Wildiers, MD, on Clinical Implications of Adding Eftilagimod to Paclitaxel in Metastatic Breast Cancer

Posted: Thursday, January 6, 2022

Hans Wildiers, MD, of University Hospitals Leuven, discusses what clinicians need to know about the ongoing study of adding eftilagimod alpha to paclitaxel to treat women with hormone receptor–­positive, HER2-negative metastatic breast cancer. (Eftilagimod is a first-in-class antigen presenting cell activator.) This regimen appears to increase overall survival, especially among women older than 65.